254. Porphyria Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 72 / Drugs : 53 - (DrugBank : 16) / Drug target genes : 19 - Drug target pathways : 35
Drugs and their primary sponsors and trial info
5-probe cocktail
Alnylam Pharmaceuticals
2018 Phase 1 NCT03505853 Sweden;
A novel synthetic, orally-administered, non-peptide small molecule, which acts as
Mitsubishi Tanabe Development America Inc.
2020 Phase 3 EUCTR2019-004226-16-IT Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
ALN-60519
ALNYLAM PHARMACEUTICALS, INC.
2018 Phase 3 EUCTR2017-002432-17-IT Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Alnylam Pharmaceuticals, Inc.
2018 Phase 3 EUCTR2017-002432-17-PL Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-NL Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-FI Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-DE Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-BG Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-SE Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-GB Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-ES Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-DK Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-BE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2017 Phase 1;Phase 2 EUCTR2016-002638-54-SE Sweden;United Kingdom;United States;
2016 Phase 1;Phase 2 EUCTR2016-002638-54-GB Sweden;United Kingdom;United States;
- Phase 3 EUCTR2017-002432-17-FR Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
- Phase 3 EUCTR2017-002432-17-CZ Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
ALN-AS1
ALNYLAM PHARMACEUTICALS, INC.
2018 Phase 3 EUCTR2017-002432-17-IT Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Alnylam Pharmaceuticals, Inc.
2018 Phase 3 EUCTR2017-002432-17-PL Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-NL Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-FI Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-DE Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-BG Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-SE Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-GB Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-ES Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-DK Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-BE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2017 Phase 1;Phase 2 EUCTR2016-002638-54-SE Sweden;United Kingdom;United States;
2016 Phase 1;Phase 2 EUCTR2016-002638-54-GB Sweden;United Kingdom;United States;
- Phase 3 EUCTR2017-002432-17-FR Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
- Phase 3 EUCTR2017-002432-17-CZ Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Afamelanotide
Clinuvel Pharmaceuticals Limited
2012 Phase 3 NCT01605136 United States;
2011 Phase 3 NCT04578496 -
2010 Phase 2 NCT01097044 United States;
2010 - EUCTR2009-011018-51-IE Finland;Ireland;Netherlands;United Kingdom;
2009 Phase 3 NCT00979745 Finland;France;Germany;Ireland;Netherlands;United Kingdom;
2009 - EUCTR2009-011018-51-NL Finland;Ireland;Netherlands;United Kingdom;
2009 - EUCTR2009-011018-51-GB Finland;Ireland;Netherlands;United Kingdom;
2009 - EUCTR2009-011018-51-FI Finland;Ireland;Netherlands;United Kingdom;
2007 Phase 3 NCT04053270 -
Afamelanotide Implant
Clinuvel Pharmaceuticals Limited
- - EUCTR2007-000636-13-DE France;Germany;Italy;Netherlands;Sweden;United Kingdom;
Aminolevulinic acid
Association pour la Recherche en Medecine Interne
2021 - NCT04923516 -
CAS # in D.3.9.1 for Sodium Salt. CAS number 1639325-43-1 (Parent Acid)
Alnylam Pharmaceuticals, Inc.
2018 Phase 3 EUCTR2017-002432-17-PL Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-NL Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-FI Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-DE Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-BG Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-SE Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-GB Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-ES Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-DK Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-BE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2017 Phase 1;Phase 2 EUCTR2016-002638-54-SE Sweden;United Kingdom;United States;
- Phase 3 EUCTR2017-002432-17-FR Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
- Phase 3 EUCTR2017-002432-17-CZ Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
CAS# in D.3.9.1 for Sodium Salt. CAS number 1639325-43-1 (Parent Acid)
Alnylam Pharmaceuticals, Inc.
2016 Phase 1;Phase 2 EUCTR2016-002638-54-GB Sweden;United Kingdom;United States;
CUV1647
CLINUVEL PHARMACUETICALS LTD
2007 - EUCTR2007-000636-13-IT France;Germany;Italy;Netherlands;Sweden;United Kingdom;
Clinuvel Pharmaceuticals Limited
2010 - EUCTR2009-011018-51-IE Finland;Ireland;Netherlands;United Kingdom;
2009 - EUCTR2009-011018-51-NL Finland;Ireland;Netherlands;United Kingdom;
2009 - EUCTR2009-011018-51-GB Finland;Ireland;Netherlands;United Kingdom;
2009 - EUCTR2009-011018-51-FI Finland;Ireland;Netherlands;United Kingdom;
2008 Phase 3 EUCTR2007-000636-13-GB France;Germany;Italy;Netherlands;Sweden;United Kingdom;
2008 Phase 3 EUCTR2007-000636-13-FR France;Germany;Italy;Netherlands;Sweden;United Kingdom;
2008 - EUCTR2007-000636-13-SE France;Germany;Italy;Netherlands;Sweden;United Kingdom;
2008 - EUCTR2007-000636-13-NL France;Germany;Italy;Netherlands;Sweden;United Kingdom;
- - EUCTR2007-000636-13-DE France;Germany;Italy;Netherlands;Sweden;United Kingdom;
Chlorpromazine Hydrochloride
Cycle Pharmaceuticals Ltd.
2016 Phase 1 NCT02943213 South Africa;
Cimetidine
Amy K. Dickey, M.D.
2021 Phase 2 NCT05020184 United States;
Colestipol
Brigham and Women's Hospital
2011 Phase 2/Phase 3 NCT01422915 United States;
Concentration unit: mg milligram(s)
Clinuvel Pharmaceuticals Limited
2009 - EUCTR2009-011018-51-GB Finland;Ireland;Netherlands;United Kingdom;
Cysteine hydrochloride
Brigham and Women's Hospital
1996 Phase 3 NCT00004940 -
FDA Office of Orphan Products Development
1996 - NCT00004831 -
Deferasirox
University of Texas Southwestern Medical Center
2008 Phase 3 NCT00599326 United States;
Dersimelagon
Mitsubishi Tanabe Development America Inc.
2020 Phase 3 EUCTR2019-004226-16-IT Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
Mitsubishi Tanabe Pharma Development America (MTDA), Inc.
2022 Phase 3 EUCTR2021-001831-17-ES Canada;Germany;Japan;Spain;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004226-16-FI Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004226-16-DE Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004226-16-SE Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004226-16-GB Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-001831-17-SE Australia;Canada;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-001831-17-DE Australia;Canada;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2019-004226-16-NO Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
Exjade
Assistance Publique - Hôpitaux de Paris
2011 Phase 2 NCT01284946 France;
Givosiran
ALNYLAM PHARMACEUTICALS, INC.
2018 Phase 3 EUCTR2017-002432-17-IT Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Alnylam Pharmaceuticals
2019 - NCT04056481 Australia;Belgium;Canada;France;Germany;Luxembourg;Netherlands;Spain;Sweden;United States;
2018 Phase 1 NCT03505853 Sweden;
2017 Phase 3 NCT03338816 Australia;Belgium;Bulgaria;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Alnylam Pharmaceuticals, Inc.
2018 Phase 3 EUCTR2017-002432-17-PL Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-NL Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-FI Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-DE Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-BG Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-SE Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-GB Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-ES Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-DK Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-BE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2017 Phase 1;Phase 2 EUCTR2016-002638-54-SE Sweden;United Kingdom;United States;
2016 Phase 1;Phase 2 EUCTR2016-002638-54-GB Sweden;United Kingdom;United States;
- Phase 3 EUCTR2017-002432-17-FR Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
- Phase 3 EUCTR2017-002432-17-CZ Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Fujii Norihisa
2021 - JPRN-jRCT2071200074 Japan;
Givosiran (ALN-AS1)
Alnylam Pharmaceuticals
2016 Phase 1/Phase 2 NCT02949830 Sweden;United Kingdom;United States;
2015 Phase 1 NCT02452372 Sweden;United Kingdom;United States;
Glucose
The University of Texas Medical Branch, Galveston
2014 Phase 2 NCT02180412 United States;
Harvoni
Wake Forest University Health Sciences
2017 Phase 2 NCT03118674 United States;
Heme arginate
National Center for Research Resources (NCRR)
1998 Phase 1 NCT00004398 -
1998 Phase 1 NCT00004397 -
1997 Phase 2 NCT00004396 United States;
1993 Phase 1/Phase 2 NCT00004789 -
Hemin
The University of Texas Medical Branch, Galveston
2014 - NCT02935400 United States;
Hemin for injection
The University of Texas Medical Branch, Galveston
2015 Phase 2 NCT02922413 United States;
Hydroxychloroquine
The University of Texas Medical Branch, Galveston
2006 Phase 2 NCT01573754 United States;
Isoniazid
University of Utah
2012 - NCT01550705 United States;
Luteinizing hormone-releasing factor
National Center for Research Resources (NCRR)
1987 - NCT00004330 United States;
MT-7117
Mitsubishi Tanabe Development America Inc.
2020 Phase 3 EUCTR2019-004226-16-IT Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
Mitsubishi Tanabe Pharma Development America (MTDA), Inc.
2022 Phase 3 EUCTR2021-001831-17-ES Canada;Germany;Japan;Spain;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004226-16-FI Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004226-16-DE Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004226-16-SE Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004226-16-GB Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-001831-17-SE Australia;Canada;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-001831-17-DE Australia;Canada;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2019-004226-16-NO Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
Mitsubishi Tanabe Pharma Development America, Inc.
2021 Phase 3 NCT05005975 Australia;Canada;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
MT-7117 High Dose
Mitsubishi Tanabe Pharma Development America, Inc.
2020 Phase 3 NCT04402489 Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
MT-7117 Low Dose
Mitsubishi Tanabe Pharma Development America, Inc.
2020 Phase 3 NCT04402489 Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
MT-7117 high dose
Mitsubishi Tanabe Pharma Development America, Inc.
2018 Phase 2 NCT03520036 United States;
MT-7117 low dose
Mitsubishi Tanabe Pharma Development America, Inc.
2018 Phase 2 NCT03520036 United States;
Nle4,D-Phe7]-a-melanocyte stimulating hormone or NDP-a-MSH
Clinuvel Pharmaceuticals Limited
- - EUCTR2007-000636-13-DE France;Germany;Italy;Netherlands;Sweden;United Kingdom;
Nle4-D-Phe7-alpha-MSH
CLINUVEL PHARMACUETICALS LTD
2007 - EUCTR2007-000636-13-IT France;Germany;Italy;Netherlands;Sweden;United Kingdom;
Oral Iron
Icahn School of Medicine at Mount Sinai
2016 - NCT02979249 United States;
Panhematin
The University of Texas Medical Branch, Galveston
2014 Phase 2 NCT02180412 United States;
Phlebotomy
The University of Texas Medical Branch, Galveston
2006 Phase 2 NCT01573754 United States;
Porphobilinogen
Association pour la Recherche en Medecine Interne
2021 - NCT04923516 -
Questran
Guy's & St Thomas' NHS Foundation Trust
2007 Phase 4 EUCTR2007-002863-28-GB United Kingdom;
Recombinant human porphobilinogen deaminase (Porphozym)
Zymenex A/S
2003 Phase 2/Phase 3 NCT00418795 United States;
Sterile Normal Saline ( NaCl)
Alnylam Pharmaceuticals
2015 Phase 1 NCT02452372 Sweden;United Kingdom;United States;
Tin mesoporphyrin
National Center for Research Resources (NCRR)
1998 Phase 1 NCT00004398 -
1998 Phase 1 NCT00004397 -
1997 Phase 2 NCT00004396 United States;
1993 Phase 1/Phase 2 NCT00004789 -
Alnylam Pharmaceuticals
2018 Phase 1 NCT03505853 Sweden;
A novel synthetic, orally-administered, non-peptide small molecule, which acts as
Mitsubishi Tanabe Development America Inc.
2020 Phase 3 EUCTR2019-004226-16-IT Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
ALN-60519
ALNYLAM PHARMACEUTICALS, INC.
2018 Phase 3 EUCTR2017-002432-17-IT Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Alnylam Pharmaceuticals, Inc.
2018 Phase 3 EUCTR2017-002432-17-PL Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-NL Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-FI Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-DE Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-BG Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-SE Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-GB Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-ES Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-DK Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-BE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2017 Phase 1;Phase 2 EUCTR2016-002638-54-SE Sweden;United Kingdom;United States;
2016 Phase 1;Phase 2 EUCTR2016-002638-54-GB Sweden;United Kingdom;United States;
- Phase 3 EUCTR2017-002432-17-FR Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
- Phase 3 EUCTR2017-002432-17-CZ Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
ALN-AS1
ALNYLAM PHARMACEUTICALS, INC.
2018 Phase 3 EUCTR2017-002432-17-IT Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Alnylam Pharmaceuticals, Inc.
2018 Phase 3 EUCTR2017-002432-17-PL Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-NL Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-FI Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-DE Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-BG Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-SE Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-GB Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-ES Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-DK Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-BE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2017 Phase 1;Phase 2 EUCTR2016-002638-54-SE Sweden;United Kingdom;United States;
2016 Phase 1;Phase 2 EUCTR2016-002638-54-GB Sweden;United Kingdom;United States;
- Phase 3 EUCTR2017-002432-17-FR Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
- Phase 3 EUCTR2017-002432-17-CZ Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Afamelanotide
Clinuvel Pharmaceuticals Limited
2012 Phase 3 NCT01605136 United States;
2011 Phase 3 NCT04578496 -
2010 Phase 2 NCT01097044 United States;
2010 - EUCTR2009-011018-51-IE Finland;Ireland;Netherlands;United Kingdom;
2009 Phase 3 NCT00979745 Finland;France;Germany;Ireland;Netherlands;United Kingdom;
2009 - EUCTR2009-011018-51-NL Finland;Ireland;Netherlands;United Kingdom;
2009 - EUCTR2009-011018-51-GB Finland;Ireland;Netherlands;United Kingdom;
2009 - EUCTR2009-011018-51-FI Finland;Ireland;Netherlands;United Kingdom;
2007 Phase 3 NCT04053270 -
Afamelanotide Implant
Clinuvel Pharmaceuticals Limited
- - EUCTR2007-000636-13-DE France;Germany;Italy;Netherlands;Sweden;United Kingdom;
Aminolevulinic acid
Association pour la Recherche en Medecine Interne
2021 - NCT04923516 -
CAS # in D.3.9.1 for Sodium Salt. CAS number 1639325-43-1 (Parent Acid)
Alnylam Pharmaceuticals, Inc.
2018 Phase 3 EUCTR2017-002432-17-PL Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-NL Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-FI Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-DE Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-BG Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-SE Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-GB Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-ES Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-DK Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-BE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2017 Phase 1;Phase 2 EUCTR2016-002638-54-SE Sweden;United Kingdom;United States;
- Phase 3 EUCTR2017-002432-17-FR Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
- Phase 3 EUCTR2017-002432-17-CZ Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
CAS# in D.3.9.1 for Sodium Salt. CAS number 1639325-43-1 (Parent Acid)
Alnylam Pharmaceuticals, Inc.
2016 Phase 1;Phase 2 EUCTR2016-002638-54-GB Sweden;United Kingdom;United States;
CUV1647
CLINUVEL PHARMACUETICALS LTD
2007 - EUCTR2007-000636-13-IT France;Germany;Italy;Netherlands;Sweden;United Kingdom;
Clinuvel Pharmaceuticals Limited
2010 - EUCTR2009-011018-51-IE Finland;Ireland;Netherlands;United Kingdom;
2009 - EUCTR2009-011018-51-NL Finland;Ireland;Netherlands;United Kingdom;
2009 - EUCTR2009-011018-51-GB Finland;Ireland;Netherlands;United Kingdom;
2009 - EUCTR2009-011018-51-FI Finland;Ireland;Netherlands;United Kingdom;
2008 Phase 3 EUCTR2007-000636-13-GB France;Germany;Italy;Netherlands;Sweden;United Kingdom;
2008 Phase 3 EUCTR2007-000636-13-FR France;Germany;Italy;Netherlands;Sweden;United Kingdom;
2008 - EUCTR2007-000636-13-SE France;Germany;Italy;Netherlands;Sweden;United Kingdom;
2008 - EUCTR2007-000636-13-NL France;Germany;Italy;Netherlands;Sweden;United Kingdom;
- - EUCTR2007-000636-13-DE France;Germany;Italy;Netherlands;Sweden;United Kingdom;
Chlorpromazine Hydrochloride
Cycle Pharmaceuticals Ltd.
2016 Phase 1 NCT02943213 South Africa;
Cimetidine
Amy K. Dickey, M.D.
2021 Phase 2 NCT05020184 United States;
Colestipol
Brigham and Women's Hospital
2011 Phase 2/Phase 3 NCT01422915 United States;
Concentration unit: mg milligram(s)
Clinuvel Pharmaceuticals Limited
2009 - EUCTR2009-011018-51-GB Finland;Ireland;Netherlands;United Kingdom;
Cysteine hydrochloride
Brigham and Women's Hospital
1996 Phase 3 NCT00004940 -
FDA Office of Orphan Products Development
1996 - NCT00004831 -
Deferasirox
University of Texas Southwestern Medical Center
2008 Phase 3 NCT00599326 United States;
Dersimelagon
Mitsubishi Tanabe Development America Inc.
2020 Phase 3 EUCTR2019-004226-16-IT Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
Mitsubishi Tanabe Pharma Development America (MTDA), Inc.
2022 Phase 3 EUCTR2021-001831-17-ES Canada;Germany;Japan;Spain;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004226-16-FI Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004226-16-DE Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004226-16-SE Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004226-16-GB Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-001831-17-SE Australia;Canada;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-001831-17-DE Australia;Canada;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2019-004226-16-NO Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
Exjade
Assistance Publique - Hôpitaux de Paris
2011 Phase 2 NCT01284946 France;
Givosiran
ALNYLAM PHARMACEUTICALS, INC.
2018 Phase 3 EUCTR2017-002432-17-IT Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Alnylam Pharmaceuticals
2019 - NCT04056481 Australia;Belgium;Canada;France;Germany;Luxembourg;Netherlands;Spain;Sweden;United States;
2018 Phase 1 NCT03505853 Sweden;
2017 Phase 3 NCT03338816 Australia;Belgium;Bulgaria;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Alnylam Pharmaceuticals, Inc.
2018 Phase 3 EUCTR2017-002432-17-PL Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-NL Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-FI Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-DE Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002432-17-BG Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-SE Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-GB Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-ES Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-DK Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2017-002432-17-BE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2017 Phase 1;Phase 2 EUCTR2016-002638-54-SE Sweden;United Kingdom;United States;
2016 Phase 1;Phase 2 EUCTR2016-002638-54-GB Sweden;United Kingdom;United States;
- Phase 3 EUCTR2017-002432-17-FR Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
- Phase 3 EUCTR2017-002432-17-CZ Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Fujii Norihisa
2021 - JPRN-jRCT2071200074 Japan;
Givosiran (ALN-AS1)
Alnylam Pharmaceuticals
2016 Phase 1/Phase 2 NCT02949830 Sweden;United Kingdom;United States;
2015 Phase 1 NCT02452372 Sweden;United Kingdom;United States;
Glucose
The University of Texas Medical Branch, Galveston
2014 Phase 2 NCT02180412 United States;
Harvoni
Wake Forest University Health Sciences
2017 Phase 2 NCT03118674 United States;
Heme arginate
National Center for Research Resources (NCRR)
1998 Phase 1 NCT00004398 -
1998 Phase 1 NCT00004397 -
1997 Phase 2 NCT00004396 United States;
1993 Phase 1/Phase 2 NCT00004789 -
Hemin
The University of Texas Medical Branch, Galveston
2014 - NCT02935400 United States;
Hemin for injection
The University of Texas Medical Branch, Galveston
2015 Phase 2 NCT02922413 United States;
Hydroxychloroquine
The University of Texas Medical Branch, Galveston
2006 Phase 2 NCT01573754 United States;
Isoniazid
University of Utah
2012 - NCT01550705 United States;
Luteinizing hormone-releasing factor
National Center for Research Resources (NCRR)
1987 - NCT00004330 United States;
MT-7117
Mitsubishi Tanabe Development America Inc.
2020 Phase 3 EUCTR2019-004226-16-IT Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
Mitsubishi Tanabe Pharma Development America (MTDA), Inc.
2022 Phase 3 EUCTR2021-001831-17-ES Canada;Germany;Japan;Spain;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004226-16-FI Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004226-16-DE Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004226-16-SE Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004226-16-GB Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-001831-17-SE Australia;Canada;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-001831-17-DE Australia;Canada;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2019-004226-16-NO Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
Mitsubishi Tanabe Pharma Development America, Inc.
2021 Phase 3 NCT05005975 Australia;Canada;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
MT-7117 High Dose
Mitsubishi Tanabe Pharma Development America, Inc.
2020 Phase 3 NCT04402489 Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
MT-7117 Low Dose
Mitsubishi Tanabe Pharma Development America, Inc.
2020 Phase 3 NCT04402489 Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
MT-7117 high dose
Mitsubishi Tanabe Pharma Development America, Inc.
2018 Phase 2 NCT03520036 United States;
MT-7117 low dose
Mitsubishi Tanabe Pharma Development America, Inc.
2018 Phase 2 NCT03520036 United States;
Nle4,D-Phe7]-a-melanocyte stimulating hormone or NDP-a-MSH
Clinuvel Pharmaceuticals Limited
- - EUCTR2007-000636-13-DE France;Germany;Italy;Netherlands;Sweden;United Kingdom;
Nle4-D-Phe7-alpha-MSH
CLINUVEL PHARMACUETICALS LTD
2007 - EUCTR2007-000636-13-IT France;Germany;Italy;Netherlands;Sweden;United Kingdom;
Oral Iron
Icahn School of Medicine at Mount Sinai
2016 - NCT02979249 United States;
Panhematin
The University of Texas Medical Branch, Galveston
2014 Phase 2 NCT02180412 United States;
Phlebotomy
The University of Texas Medical Branch, Galveston
2006 Phase 2 NCT01573754 United States;
Porphobilinogen
Association pour la Recherche en Medecine Interne
2021 - NCT04923516 -
Questran
Guy's & St Thomas' NHS Foundation Trust
2007 Phase 4 EUCTR2007-002863-28-GB United Kingdom;
Recombinant human porphobilinogen deaminase (Porphozym)
Zymenex A/S
2003 Phase 2/Phase 3 NCT00418795 United States;
Sterile Normal Saline ( NaCl)
Alnylam Pharmaceuticals
2015 Phase 1 NCT02452372 Sweden;United Kingdom;United States;
Tin mesoporphyrin
National Center for Research Resources (NCRR)
1998 Phase 1 NCT00004398 -
1998 Phase 1 NCT00004397 -
1997 Phase 2 NCT00004396 United States;
1993 Phase 1/Phase 2 NCT00004789 -